Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Drug Pricing topic
No spam. Unsubscribe anytime.
Sponsors and patients press for caps on insulin and epinephrine costs; students and advocates testify
Summary
Representative Sean Boucher presented House Bill 1195 to address high consumer costs for insulin and epinephrine auto-injectors; students, patients and advocacy groups testified in support, citing national price hikes, rationing and state models in other states; insurers asked for technical work with sponsors.
Representative Sean Boucher (presenting as sponsor) told the committee House Bill 1195 aims to curb what he called “excessive rise in cost for life-saving drugs of insulin and epinephrine.” He said insulin prices have tripled over the past decade and that many patients ration insulin or skip fills when costs compete with rent or utilities.
Patient witnesses and student advocates emphasized the human toll. Multiple student speakers from Saint Louis University Health Policy Pod and family members told the committee about relatives who rationed or missed doses because of cost; they cited studies showing premium impacts are small when states adopt insulin copay caps. Witnesses also described compounding pharmacies that will produce alpha-gal–safe or preservative-free medications only for cash and the high costs of compounded formulations for patients with special needs.
A number of supporters pointed to the federal Inflation Reduction Act’s insulin cap for Medicare beneficiaries and to 25 states that have enacted state-level caps. Hampton Williams of the Missouri Insurance Coalition testified for information and said coalition members would work with the sponsor on language; he noted many insurers already offer plans with $35 insulin copay options and that the sponsor and industry should discuss implementation details such as whether the cap applies to a 30‑day supply or a single prescription event and how auto-injectors should be handled.
Committee members asked about program design, how an epinephrine provision would apply to injectors or newer nasal forms, and about whether caps would materially increase premiums; witnesses and advocates cited analyses showing small premium impacts in other states.
Why it matters: Witnesses and the sponsor framed the bill as a response to documented price increases that have led some patients to ration insulin and face life‑threatening risks; they argued state-level action can complement federal programs.
What’s next: Insurer representatives said they would work with the sponsor on drafting technical language; the hearing closed with no recorded committee vote.
